Nano Cures announced $90M pre-IPO funding round

Nano Cures announced $90M pre-IPO funding round

Nano Cures, a clinical stage biotechnology and infectious disease immunity platform company, today announced a $90M pre-IPO funding round. The investment will be led by a $20M commitment from Opulence Capital Management, a Dubai based private investment fund, with existing and new investors participating.

The investment will accelerate the global scale up of Nano’s Cures Platform for Covid-19 variants, including vaccines and persistent immunity delivery. Nano’s novel self- administered technology moves delivery beyond syringes and shots, to an array of nasal, dermal, ophthalmic, sub-lingual, and oral options. Nano will open up its Cures Platform to other pharmaceutical companies and their vaccines, providing dynamic new ways to conquer the pandemic and deliver billions of doses directly to those in need.

“As Covid-19 has made abundantly clear, a 21st century technology-enabled approach is needed that refreshes how we proactively solve public health challenges and threats. The opportunity to do so is likely the largest value creation opportunity in the world today. The Nano Cures Platform for Covid-19 variants is the solution,” said Steve Papermaster, Nano’s Chief Executive Officer.

Nano is accelerating plans to bring its Cures Platform for Covid-19 (and variants) to emerging regions such as GCC, Southeast Asia, Latin America and Central/Southern Europe. The breakthroughs in disruptive delivery methods beyond shots will be a gamechanger for improving access and vaccine delivery to people of all regions.

“We are proud to support and partner with Nano as they bring this Cures Platform to market. We believe they are delivering a highly unique set of proactive health and safety solutions to address the current global pandemic, as well as safeguard against the next one,” said Alexander Vanderhey, Chairman of Opulence Capital Management. “With this investment, we are envisioning a safer, healthier future for the world.”

Furthermore, Nano is developing universal pan coronavirus vaccines and therapeutics for annual protection against known and emerging coronaviruses, which will be critical to successfully avoiding future global and regional public health and economic threats.

“The rollout of the Nano Cures Platform will help to heal the world from the current devastating Covid-19 pandemic, and shield the world from future pandemics, epidemics, and unnecessary death from infectious diseases,” said Papermaster.

Lost Password